Please assess the completion status of the following clinical trial:

Trial Title: Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* The subject must have evidence supportive of a PCD diagnosis.~* Subjects with percent predicted FEV1 of ≥40 to \<90 percentage points~* Non-smoker for at least 90 days prior to the Screening Visit and less than a 5 pack-year lifetime history of smoking~* Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1~* If currently using daily inhaled HS, must be able to discontinue its use for the duration of the study.~* If taking daily chronic or chronic cycling antibiotics, has been on a consistent regimen for at least 4 months prior to the Screening Visit.~* Clinically stable (as deemed by the investigator) for at least 14 days prior to the Screening Visit~* Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit. Subjects of childbearing potential and who are sexually active must meet the contraception requirements.~Exclusion Criteria:~* Diagnosis of CF based on results of sweat chloride or nasal potential difference (NPD) tests or presence of 2 CF-causing mutations in CFTR gene.~* History of any organ transplantation or lung resection or chest wall surgery.~* Significant congenital heart defects, other than a laterality defect, at the discretion of the investigator~* Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome).~* Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic visit and long-acting bronchodilator use the night before the first and last clinic visit of each treatment period.~* Use of diuretics (including amiloride) or renin-angiotensin antihypertensive drugs~* Symptoms of acute upper or lower respiratory tract infection, acute pulmonary exacerbation, or treatment or was treated with systemic antibiotics for ear or sinus disease within 28 days before Day 1 (topical otic antibiotics allowed).~* History of significant intolerance to inhaled HS~* Pregnant and/or nursing females~* Any clinically significant laboratory abnormalities~* History of chronic B. cepacia complex or M. abscessus or M. avium~* Surgery that required general anesthesia and hospitalization within 3 months of Day 1~Additional Exclusion Criteria for Part B:~* In addition to the exclusion criteria above, subjects who participate in Part B and meet any of the following exclusion criteria will not be eligible to continue into Part B~* Unable to swallow tablets.~* Concomitant use of strong or moderate inhibitors or inducers of cytochrome P450 (CYP) 3A, including consumption of certain herbal medications (e.g., St. John's Wort), and grapefruit/grapefruit juice.~* Known hypersensitivity to ivacaftor.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: VX-371 in Hypertonic Saline (HS), Then HS (Type: EXPERIMENTAL): Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
- Part A: HS, Then VX-371 in HS (Type: EXPERIMENTAL): Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
- Part A: VX-371, Then Placebo (Type: EXPERIMENTAL): Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
- Part A: Placebo, Then VX-371 (Type: EXPERIMENTAL): Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
- Part B: VX-371 in HS + Ivacaftor (Type: EXPERIMENTAL): Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
- Part B: HS + Ivacaftor (Type: EXPERIMENTAL): Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
- Part B: VX-371 + Ivacaftor (Type: EXPERIMENTAL): Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
- Part B: Placebo + Ivacaftor (Type: PLACEBO_COMPARATOR): Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).